MAXCYTE INC

For the period ended Mar 31, 2024. Filed May 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2024 · Filed May 7, 2024

MXCT$1.13-13.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

Unaudited Condensed Consolidated Statements of Cash Flow****s

(in thousands)


	Three Months Ended March 31,
· · 2024 · 2023
Cash flows from operating activities: · ·
Net loss		$(9,526)	$(10,882)

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		1,111	962
Non-cash lease expense		116	96
Net book value of consigned equipment sold		11	17
Stock-based compensation		3,015	3,277
Recoveries of bad debt		130	—
Amortization of discounts on investments		(1,983)	(1,730)

Changes in operating assets and liabilities:
Accounts receivable		(343)	3,399
Accounts receivable - TIA		—	916
Inventory		169	(1,706)
Prepaid expense and other current assets		689	509
Other assets		33	410
Accounts payable, accrued expenses and other		(3,286)	1,227
Operating lease liability		(103)	157
Deferred revenue		(593)	(963)
Other liabilities		(4)	(13)
Net cash used in operating activities		(10,564)	(4,324)

Cash flows from investing activities:
Purchases of investments		(48,042)	(57,814)
Maturities of investments		34,450	89,000
Purchases of property and equipment		(804)	(1,558)
Proceeds from sale of equipment		-	9
Net cash (used in) provided by investing activities		(14,396)	29,637

Cash flows from financing activities:
Proceeds from exercise of stock options		703	1,456
Net cash provided by financing activities		703	1,456
Net (decrease) increase in cash and cash equivalents		(24,257)	26,769
Cash and cash equivalents, beginning of period		46,506	11,064
Cash and cash equivalents, end of period		$22,249	$37,833

Supplemental disclosure of non-cash investing and financing activities:
Property and equipment purchases included in accounts payable and accrued expenses		$16	$631

MaxCyte, Inc.

Notes to Condensed Consolidated Financial Statements

(in thousands, except par value, share and per share amounts)

(Unaudited)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.